

# Luisa Imberti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3389538/publications.pdf>

Version: 2024-02-01

38  
papers

5,913  
citations

304368

22  
h-index

329751

37  
g-index

43  
all docs

43  
docs citations

43  
times ranked

10530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. <i>Science Immunology</i> , 2023, 8, .	5.6	35
2	Human genetic and immunological determinants of critical COVID-19 pneumonia. <i>Nature</i> , 2022, 603, 587-598.	13.7	216
3	Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. <i>Nature Medicine</i> , 2022, 28, 1050-1062.	15.2	144
4	Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children With MIS-C. <i>Frontiers in Immunology</i> , 2022, 13, 841126.	2.2	18
5	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	3.3	110
6	Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients. , 2022, 1, .		5
7	Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. <i>Blood</i> , 2022, 140, 1650-1655.	0.6	10
8	An immune-based biomarker signature is associated with mortality in COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	2.3	269
9	Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. <i>Cell</i> , 2021, 184, 1836-1857.e22.	13.5	167
10	Sex differences in a cohort of COVID-19 Italian patients hospitalized during the first and second pandemic waves. <i>Biology of Sex Differences</i> , 2021, 12, 45.	1.8	13
11	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	5.6	357
12	Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. <i>Blood Cancer Journal</i> , 2021, 11, 151.	2.8	32
13	Age-Related Lymphocyte Output During Disease-Modifying Therapies for Multiple Sclerosis. <i>Drugs and Aging</i> , 2020, 37, 739-746.	1.3	7
14	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,749
15	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
16	Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection. <i>Journal of Neuroimmunology</i> , 2020, 345, 577282.	1.1	20
17	Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon- $\hat{1}^2$ therapy of multiple sclerosis patients. <i>Journal of Translational Medicine</i> , 2020, 18, 169.	1.8	3
18	Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy. <i>Scientific Reports</i> , 2019, 9, 16605.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Circulating microRNAs and Their Role in Multiple Myeloma. <i>Non-coding RNA</i> , 2019, 5, 37.	1.3	10
20	Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1196-1201.	1.4	34
21	Detection of newly produced T and B lymphocytes by digital PCR in blood stored dry on nylon flocked swabs. <i>Journal of Translational Medicine</i> , 2017, 15, 70.	1.8	13
22	Exosomes in Tumor Angiogenesis. <i>Methods in Molecular Biology</i> , 2016, 1464, 25-34.	0.4	32
23	Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 726-734.	1.4	34
24	Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy. <i>Journal of Neuroimmunology</i> , 2014, 277, 6-12.	1.1	6
25	Long-Lasting Production of New T and B Cells and T-Cell Repertoire Diversity in Patients with Primary Immunodeficiency Who Had Undergone Stem Cell Transplantation: A Single-Centre Experience. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	1
26	Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation. <i>Journal of Translational Medicine</i> , 2013, 11, 188.	1.8	46
27	<scp> </scp> -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. <i>Neurology</i> , 2013, 81, 865-871.	1.5	140
28	Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. <i>Multiple Sclerosis Journal</i> , 2012, 18, 788-798.	1.4	19
29	Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. <i>Clinical Immunology</i> , 2012, 145, 19-26.	1.4	24
30	Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients. <i>Journal of Translational Medicine</i> , 2012, 10, 94.	1.8	15
31	Pre-Existing T- and B-Cell Defects in One Progressive Multifocal Leukoencephalopathy Patient. <i>PLoS ONE</i> , 2012, 7, e34493.	1.1	21
32	Thymic and Bone Marrow Output in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2011, 31, 540-549.	2.0	35
33	Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. <i>Clinical Immunology</i> , 2010, 136, 217-227.	1.4	108
34	Transfer of myxovirus-protein-A mRNA assay for interferon- $\hat{1}^2$ bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1235-1238.	1.4	11
35	The Different Extent of B and T Cell Immune Reconstitution after Hematopoietic Stem Cell Transplantation and Enzyme Replacement Therapies in SCID Patients with Adenosine Deaminase Deficiency. <i>Journal of Immunology</i> , 2010, 185, 7713-7722.	0.4	62
36	Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 892-899.	1.5	95

#	ARTICLE	IF	CITATIONS
37	IFN $\gamma$ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. <i>Journal of Neuroimmunology</i> , 2007, 189, 102-110.	1.1	29
38	Assessment of T-Cell receptor $\beta$ -chain diversity by heteroduplex analysis. <i>Human Immunology</i> , 1996, 48, 12-22.	1.2	26